Jason Napodano, CFA
Research analyst, medium-term horizon, biotech, small-cap

Alkermes Changing The Standard Of Care For Schizophrenia

By Jason Napodano, CFA, And John Tucker, PhD

Ask a scientist or healthcare portfolio manager what the hot topics are in biotechnology today, and you will likely hear about cancer immunotherapy, stem cells, RNA interference and exon-skipping technologies. One subject they will probably not bring up is the reformulation of 20 year old drugs. Yet, Ireland-based Alkermes plc (NASDAQ:ALKS) has grown into a $4 billion company in part by doing exactly that.

As it's impossible to do justice to Alkermes' entire portfolio of products and drug delivery technologies in a single article, we'll focus instead on the company's efforts in the rapidly growing market for long-acting injectable (LAI) drugs for the treatment of schizophrenia. Below, we discuss how...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details